Aveanna Healthcare (AVAH)
Market Price (5/3/2026): $6.615 | Market Cap: $1.4 BilSector: Health Care | Industry: Health Care Facilities
Aveanna Healthcare (AVAH)
Market Price (5/3/2026): $6.615Market Cap: $1.4 BilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 16%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 12%, FCF Yield is 8.6% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -30% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Chronic Disease Management, Show more. | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 95% Key risksAVAH key risks include [1] margin pressure on its core Private Duty Services segment from persistent labor shortages and wage inflation and [2] significant interest rate exposure due to its substantial variable-rate debt. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 16%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 12%, FCF Yield is 8.6% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -30% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Chronic Disease Management, Show more. |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 95% |
| Key risksAVAH key risks include [1] margin pressure on its core Private Duty Services segment from persistent labor shortages and wage inflation and [2] significant interest rate exposure due to its substantial variable-rate debt. |
Qualitative Assessment
AI Analysis | Feedback
1. Aveanna Healthcare's full-year 2026 guidance fell short of analyst expectations, leading to a tempered outlook for future profitability. Despite reporting strong Q4 2025 results with revenue of $662.5 million and adjusted EBITDA of $85.0 million, the company maintained its 2026 revenue guidance between $2.54 billion and $2.56 billion. This guidance was at or slightly below the analyst consensus of $2.56 billion for revenue. Furthermore, analysts forecast Aveanna's earnings to decline by 16.7% per annum over the next three years, with EPS projected to decrease by 19.5% annually.
2. Multiple analyst firms reduced their price targets for Aveanna Healthcare during the period. Following the company's Q4 2025 earnings release and updated guidance, Barclays decreased its price target from $11.00 to $9.50 on March 25, 2026. Similarly, Truist Financial lowered its price objective from $9.00 to $8.00 on April 13, 2026. These downward revisions signal a less optimistic sentiment from market analysts regarding the stock's near-term potential.
Show more
Stock Movement Drivers
Fundamental Drivers
The -21.3% change in AVAH stock from 1/31/2026 to 5/3/2026 was primarily driven by a -73.5% change in the company's P/E Multiple.| (LTM values as of) | 1312026 | 5032026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.40 | 6.62 | -21.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,291 | 2,433 | 6.2% |
| Net Income Margin (%) | 3.3% | 9.2% | 180.7% |
| P/E Multiple | 23.3 | 6.2 | -73.5% |
| Shares Outstanding (Mil) | 209 | 210 | -0.3% |
| Cumulative Contribution | -21.3% |
Market Drivers
1/31/2026 to 5/3/2026| Return | Correlation | |
|---|---|---|
| AVAH | -21.3% | |
| Market (SPY) | 3.6% | 37.1% |
| Sector (XLV) | -5.8% | 23.3% |
Fundamental Drivers
The -26.9% change in AVAH stock from 10/31/2025 to 5/3/2026 was primarily driven by a -93.7% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 5032026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.05 | 6.62 | -26.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,178 | 2,433 | 11.7% |
| Net Income Margin (%) | 0.9% | 9.2% | 985.4% |
| P/E Multiple | 98.0 | 6.2 | -93.7% |
| Shares Outstanding (Mil) | 201 | 210 | -4.1% |
| Cumulative Contribution | -26.9% |
Market Drivers
10/31/2025 to 5/3/2026| Return | Correlation | |
|---|---|---|
| AVAH | -27.0% | |
| Market (SPY) | 5.5% | 30.2% |
| Sector (XLV) | 1.5% | 27.8% |
Fundamental Drivers
The 43.5% change in AVAH stock from 4/30/2025 to 5/3/2026 was primarily driven by a 29.4% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5032026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.61 | 6.62 | 43.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,025 | 2,433 | 20.2% |
| P/S Multiple | 0.4 | 0.6 | 29.4% |
| Shares Outstanding (Mil) | 193 | 210 | -7.7% |
| Cumulative Contribution | 43.5% |
Market Drivers
4/30/2025 to 5/3/2026| Return | Correlation | |
|---|---|---|
| AVAH | 43.4% | |
| Market (SPY) | 30.4% | 24.5% |
| Sector (XLV) | 5.2% | 10.0% |
Fundamental Drivers
The 437.8% change in AVAH stock from 4/30/2023 to 5/3/2026 was primarily driven by a 344.5% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5032026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.23 | 6.62 | 437.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,788 | 2,433 | 36.1% |
| P/S Multiple | 0.1 | 0.6 | 344.5% |
| Shares Outstanding (Mil) | 186 | 210 | -11.1% |
| Cumulative Contribution | 437.8% |
Market Drivers
4/30/2023 to 5/3/2026| Return | Correlation | |
|---|---|---|
| AVAH | 437.4% | |
| Market (SPY) | 78.7% | 27.8% |
| Sector (XLV) | 14.3% | 20.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AVAH Return | -36% | -89% | 244% | 71% | 79% | -20% | -43% |
| Peers Return | 14% | -5% | -1% | 15% | 35% | 5% | 76% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 5% | 92% |
Monthly Win Rates [3] | |||||||
| AVAH Win Rate | 33% | 17% | 50% | 58% | 58% | 50% | |
| Peers Win Rate | 47% | 41% | 50% | 60% | 62% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| AVAH Max Drawdown | -47% | -91% | -9% | -19% | -19% | -24% | |
| Peers Max Drawdown | -23% | -40% | -23% | -20% | -11% | -13% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ADUS, EHAB, EHC, OPCH, BTSG.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/1/2026 (YTD)
How Low Can It Go
| Event | AVAH | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -26.5% | -18.8% |
| % Gain to Breakeven | 36.1% | 23.1% |
| Time to Breakeven | 3 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -39.1% | -9.5% |
| % Gain to Breakeven | 64.2% | 10.5% |
| Time to Breakeven | 33 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -22.0% | -6.7% |
| % Gain to Breakeven | 28.2% | 7.1% |
| Time to Breakeven | 7 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -83.9% | -24.5% |
| % Gain to Breakeven | 521.7% | 32.4% |
| Time to Breakeven | 1043 days | 427 days |
In The Past
Aveanna Healthcare's stock fell -26.5% during the 2025 US Tariff Shock. Such a loss loss requires a 36.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | AVAH | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -26.5% | -18.8% |
| % Gain to Breakeven | 36.1% | 23.1% |
| Time to Breakeven | 3 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -39.1% | -9.5% |
| % Gain to Breakeven | 64.2% | 10.5% |
| Time to Breakeven | 33 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -22.0% | -6.7% |
| % Gain to Breakeven | 28.2% | 7.1% |
| Time to Breakeven | 7 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -83.9% | -24.5% |
| % Gain to Breakeven | 521.7% | 32.4% |
| Time to Breakeven | 1043 days | 427 days |
In The Past
Aveanna Healthcare's stock fell -26.5% during the 2025 US Tariff Shock. Such a loss loss requires a 36.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Aveanna Healthcare (AVAH)
AI Analysis | Feedback
Analogy 1: Amazon for comprehensive in-home medical care and supplies.
Analogy 2: Like a specialized DoorDash or Instacart for skilled nurses, therapists, and medical supplies delivered to your home.
AI Analysis | Feedback
- Private Duty Nursing (PDN): Offers in-home skilled nursing and specialized care primarily for medically fragile children, including support in school settings and pediatric day healthcare centers.
- Pediatric Therapy Services: Provides physical, occupational, and speech therapy services for children, delivered both in-clinic and within their homes.
- Home Health Services: Delivers a range of in-home services for adults, including skilled nursing, physical, occupational, and speech therapy, as well as medical social and aide services.
- Hospice Services: Offers compassionate care and support for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments.
- Enteral Nutrition & Medical Supplies: Supplies specialized nutritional products and other medical items for home delivery to adults and children on a periodic or as-needed basis.
AI Analysis | Feedback
Aveanna Healthcare (AVAH) primarily sells its services and products directly to individuals and their families. Based on the company description, its major customer categories include:
- Medically fragile children and their families: This category encompasses patients requiring private duty nursing (PDN) services, in-home skilled nursing, nursing services in school settings, pediatric day healthcare, and in-clinic or home-based pediatric therapy services (physical, occupational, and speech).
- Adults requiring home health and hospice services: This includes individuals needing skilled nursing care, physical, occupational, and speech therapy services, medical social and aide services, and hospice care for life-limiting illnesses.
- Individuals (children and adults) requiring enteral nutrition and other medical supplies: This category includes patients who receive enteral nutrition supplies and other related medical products delivered to their homes.
AI Analysis | Feedback
nullAI Analysis | Feedback
Jeff Shaner, President and Chief Executive Officer
Jeff Shaner was appointed President and Chief Executive Officer of Aveanna Healthcare in January 2023 and also serves on the Board of Directors. He was integral to the formation of Aveanna Healthcare in 2017 and brings over 20 years of experience in post-acute healthcare leadership. Mr. Shaner began his healthcare career in 2000 at Total Care, Inc., which was acquired by The Healthfield Group. He led the integration of multiple acquisitions at Healthfield, ultimately leading to its sale to Gentiva Health Services, Inc. in 2006. At Gentiva, he held various leadership positions, including President of the Hospice division, and led the integration of Odyssey Hospice, Inc. Following Gentiva's sale to Kindred Healthcare in 2015, he provided consulting services to private equity firms Linden Capital Partners and Blue Wolf Capital, and also served as an operating partner for these firms. He then joined PSA Healthcare as Chief Operating Officer in 2015, which was instrumental in the creation of Aveanna Healthcare.
Matt Buckhalter, Chief Financial Officer
Matt Buckhalter was appointed Chief Financial Officer of Aveanna Healthcare, effective January 1, 2024, after serving as interim CFO since July 2023. He joined Aveanna in 2016 and has been responsible for corporate and operational finance, business intelligence, financial planning and analysis, and investor relations. Previously, Mr. Buckhalter held the role of Senior Vice President of Finance, leading the company's Investor Relations Group. Before joining Aveanna, he was Vice President of Finance for RT Capital and served as a senior financial analyst for Gentiva Health Services.
Rodney Windley, Chairman of the Board
Rodney Windley serves as Chairman of the Board of Aveanna Healthcare and has a long and distinguished career spanning over 40 years in the healthcare industry. He co-founded Central Health Services in the 1980s, which was later sold to Columbia HCA. In 1989, he founded The Healthfield Group, serving as its Chairman and Chief Executive Officer until its merger with Gentiva Health Services in 2009. He then served as Vice Chairman and later Executive Chairman of Gentiva, guiding it through its merger with Kindred Healthcare in 2015. Prior to the formation of Aveanna in 2017, Mr. Windley was the Executive Chairman of PSA Healthcare. He is recognized as one of the executive founders of Aveanna Healthcare, which was formed through the combination of Epic Health Services and PSA Healthcare, backed by private equity sponsors Bain Capital and J.H. Whitney.
Jerry Perchik, Chief Legal Officer and Secretary
Jerry Perchik serves as Aveanna's Chief Legal Officer and Secretary, acting as the primary legal advisor to the CEO, senior management team, and Board of Directors. He brings over fifteen years of experience in corporate law and the healthcare industry, having previously served as Chief Legal Officer for MedQuest Associates. Mr. Perchik has held various corporate leadership and legal roles in both publicly traded and private equity-sponsored healthcare companies.
Ed Reisz, Chief Administrative Officer
Ed Reisz is the Chief Administrative Officer of Aveanna Healthcare, with over 30 years of successful experience in the Home Care industry. Before the formation of Aveanna Healthcare, Mr. Reisz held the position of Executive Vice President and Chief Human Resource Officer for PSA Healthcare. Prior to joining PSA, he was Senior Vice President and Chief Human Resource Officer for Gentiva Health Services.
AI Analysis | Feedback
The key risks to Aveanna Healthcare (AVAH) primarily revolve around its reliance on government payers, the challenging labor market for healthcare professionals, and its substantial debt load.
-
Labor Shortages and Wage Inflation: Aveanna Healthcare faces a persistent industry-wide challenge of workforce shortages, particularly for skilled nurses and therapists, which affects its ability to expand caregiver capacity. This scarcity of clinical staff leads to increased wage inflation, driving up operating costs and putting pressure on the company's margins, especially in its Private Duty Services segment. The competitive labor market, with increased competition from hospitals and travel agencies, makes it difficult to recruit and retain qualified personnel, despite the strong demand for home- and community-based care.
-
Reimbursement Rate Pressures and Regulatory Changes: A significant portion of Aveanna's revenue, estimated between 75% and 90%, is derived from government payers such as Medicaid and Medicare. Consequently, the company is highly susceptible to unpredictable changes in Medicare/Medicaid reimbursement rates and payment methodologies, as well as broader healthcare reform and other regulations. While Aveanna actively pursues and has secured rate increases in various states, especially through its preferred payer strategy, the ongoing political risk tied to government reimbursement and state budget cycles remains a primary financial lever that can impact its profitability and revenue growth.
-
High Indebtedness and Interest Rate Risk: Aveanna Healthcare operates with substantial financial leverage, having approximately $1.49 billion in variable-rate debt as of late 2025. This high level of indebtedness makes the company vulnerable to general adverse economic conditions and limits its flexibility to pursue strategic alternatives. A "higher-for-longer" interest rate environment, characterized by elevated Secured Overnight Financing Rate (SOFR) levels, directly impacts Aveanna's cost of capital and increases its interest expense. Previous assessments have noted the company's "very high financial leverage" and potential risk of default.
AI Analysis | Feedback
The following clear emerging threats have been identified for Aveanna Healthcare (AVAH):
- Disruptive E-commerce and Direct-to-Consumer Medical Supply Platforms: Aveanna's Medical Solutions segment, which provides enteral nutrition supplies and other products, faces an emerging threat from large-scale e-commerce giants and specialized online retailers. These platforms can leverage superior logistics, broader product offerings, and potentially lower overhead to deliver medical supplies more efficiently and at competitive prices directly to consumers. This ongoing shift in retail, expanding into the medical supply sector, poses a direct challenge to Aveanna's distribution model by offering increased convenience and potentially lower costs, akin to the Netflix disruption of Blockbuster.
- Technology-Enabled Direct Caregiver-to-Patient Platforms: For Aveanna's Private Duty Services (PDS) and Home Health & Hospice (HHH) segments, particularly for personal care services, medical social services, aide services, and less complex therapy, there is an emerging threat from technology-driven platforms that directly connect patients/families with qualified independent caregivers and therapists. These "Uber-like" models aim to disintermediate traditional home care agencies by offering greater flexibility, transparent pricing, and potentially lower costs through reduced overhead. While the highly specialized and regulated nature of care for medically fragile children creates a barrier for these platforms in Aveanna's core PDN services, their expansion into broader home health and personal care markets could siphon off business from Aveanna's diversified offerings.
AI Analysis | Feedback
Aveanna Healthcare (AVAH) operates in several significant addressable markets within the United States for its main products and services:
- Private Duty Nursing (PDN) Services: The U.S. private nursing services market generated a revenue of USD 1,844.1 million in 2023. This market is projected to reach USD 2,693.6 million by 2030, exhibiting a compound annual growth rate (CAGR) of 5.6% from 2024 to 2030.
- Adult Home Health Services: The U.S. home healthcare services market size was valued at USD 100.95 billion in 2024. It is projected to grow from USD 107.07 billion in 2025 to USD 176.30 billion by 2032, with a CAGR of 7.4% during the forecast period.
- Hospice Services: The U.S. hospice market was estimated at USD 29.92 billion in 2024. This market is projected to grow at a CAGR of 4.61% from 2025 to 2030, reaching an estimated USD 39.09 billion by 2030.
- Home-based Pediatric Therapy Services: The U.S. pediatric home healthcare market was valued at USD 20.1 billion in 2024. The market is anticipated to grow from USD 21.4 billion in 2025 to USD 38.9 billion in 2034, growing at a CAGR of 6.9% from 2025 to 2034.
- Enteral Nutrition Services: The U.S. enteral nutrition products market size was valued at USD 2.84 billion in 2023. The market is projected to grow from USD 2.98 billion in 2024 to USD 4.86 billion by 2032, exhibiting a CAGR of 6.3% during the forecast period.
AI Analysis | Feedback
Aveanna Healthcare Holdings Inc. (AVAH) is expected to drive future revenue growth over the next two to three years through several key strategies:
- Expansion and Organic Growth in Home Health & Hospice Services: Aveanna Healthcare anticipates its Home Health & Hospice segment to be a significant growth engine, projecting an organic growth rate of 5% to 7% for 2026. This growth is expected to be fueled by increased patient admissions and a focus on episodic care.
- Strategic Acquisitions (Tuck-in M&A): The company is actively pursuing smaller, "tuck-in" acquisitions across its Private Duty Services, Home Health & Hospice, and Medical Solutions segments. Aveanna aims for approximately 3% annual growth from these strategic acquisitions, exemplified by its June 2025 acquisition of Thrive Skilled Pediatric Care.
- Optimization of Payer Relationships and Reimbursement Rates: Aveanna is implementing "preferred payer and government affairs strategies" to strengthen relationships with payers and government entities. These efforts are designed to secure more favorable reimbursement rates and value-based agreements, which have already contributed to increased revenue in its home health and hospice divisions.
- Increased Patient Volume and Enhanced Rates in Private Duty Services: The Private Duty Services (PDS) segment is a crucial revenue driver, with growth stemming from increased patient volumes and improved reimbursement rates. The company is focused on aligning its clinical capacity and recruitment efforts with preferred payer partners to achieve accelerated organic growth in this segment.
- Modernization of Medical Solutions and Introduction of New Offerings: Aveanna is dedicated to modernizing its Medical Solutions services and introducing new offerings to generate high-margin revenue streams. A notable initiative is the launch of a proprietary enteral nutrition supply division, which aims to capture more of the total cost of care for its medically complex patient population.
AI Analysis | Feedback
Share Issuance
- Aveanna Healthcare completed its Initial Public Offering (IPO) on April 29, 2021, offering 38,236,000 shares of common stock at $12.00 per share. Underwriters were granted an option to purchase up to an additional 5,735,400 shares.
- In October 2025, selling stockholders associated with J.H. Whitney Equity Partners VII conducted a secondary offering of 10,000,000 shares of common stock at $9.00 per share. Aveanna Healthcare did not sell any shares or receive proceeds from this offering.
Outbound Investments
- In April 2025, Aveanna announced the acquisition of Thrive Skilled Pediatric Care for $75 million, funded by a combination of common stock and cash. This acquisition was completed in June 2025.
- In 2021, the company acquired Comfort Care, an adult home health and hospice company, for $345 million.
- Also in 2021, Aveanna acquired Accredited Home Care, a private duty services company, for a base purchase price of $180 million.
Capital Expenditures
- Aveanna Healthcare's capital expenditures in the last 12 months were approximately -$7.03 million.
- In Q3 2022, capital expenditures amounted to $2.8 million, primarily used to fund long-term assets and infrastructure.
- The company is focused on investments in clinical innovation, data and analytics, recruitment, and technology to support efficient growth, and is upgrading its digital systems for scheduling, billing, and care coordination.
Latest Trefis Analyses
Trade Ideas
Select ideas related to AVAH.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 36.20 |
| Mkt Cap | 2.5 |
| Rev LTM | 4,050 |
| Op Inc LTM | 296 |
| FCF LTM | 165 |
| FCF 3Y Avg | 145 |
| CFO LTM | 190 |
| CFO 3Y Avg | 191 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 15.1% |
| Rev Chg 3Y Avg | 11.5% |
| Rev Chg Q | 17.3% |
| QoQ Delta Rev Chg LTM | 3.9% |
| Op Inc Chg LTM | 35.9% |
| Op Inc Chg 3Y Avg | 22.6% |
| Op Mgn LTM | 7.9% |
| Op Mgn 3Y Avg | 7.2% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 5.9% |
| CFO/Rev 3Y Avg | 5.5% |
| FCF/Rev LTM | 5.5% |
| FCF/Rev 3Y Avg | 4.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2.5 |
| P/S | 0.7 |
| P/Op Inc | 10.3 |
| P/EBIT | 11.1 |
| P/E | 16.2 |
| P/CFO | 11.7 |
| Total Yield | 5.9% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 4.4% |
| D/E | 0.3 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.0% |
| 3M Rtn | 4.0% |
| 6M Rtn | -10.9% |
| 12M Rtn | 15.7% |
| 3Y Rtn | 47.3% |
| 1M Excs Rtn | -4.3% |
| 3M Excs Rtn | -0.2% |
| 6M Excs Rtn | -22.2% |
| 12M Excs Rtn | -10.5% |
| 3Y Excs Rtn | -36.9% |
Price Behavior
| Market Price | $6.61 | |
| Market Cap ($ Bil) | 1.4 | |
| First Trading Date | 04/29/2021 | |
| Distance from 52W High | -35.6% | |
| 50 Days | 200 Days | |
| DMA Price | $6.78 | $7.76 |
| DMA Trend | up | down |
| Distance from DMA | -2.6% | -14.8% |
| 3M | 1YR | |
| Volatility | 40.5% | 68.7% |
| Downside Capture | 1.36 | 0.52 |
| Upside Capture | 81.85 | 106.17 |
| Correlation (SPY) | 36.1% | 24.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.41 | 1.07 | 0.97 | 1.00 | 1.35 | 1.44 |
| Up Beta | 0.47 | 0.34 | 0.74 | 1.00 | 1.90 | 1.18 |
| Down Beta | 4.11 | -0.95 | 0.00 | 0.40 | 1.64 | 1.51 |
| Up Capture | 123% | 142% | 80% | 61% | 119% | 848% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 13 | 21 | 32 | 58 | 117 | 346 |
| Down Capture | 794% | 222% | 173% | 154% | 99% | 108% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 9 | 22 | 32 | 67 | 129 | 374 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AVAH | |
|---|---|---|---|---|
| AVAH | 49.0% | 68.8% | 0.82 | - |
| Sector ETF (XLV) | 5.2% | 16.0% | 0.13 | 9.8% |
| Equity (SPY) | 30.6% | 12.5% | 1.88 | 24.2% |
| Gold (GLD) | 39.5% | 27.2% | 1.20 | 3.9% |
| Commodities (DBC) | 51.5% | 17.9% | 2.20 | -3.7% |
| Real Estate (VNQ) | 13.1% | 13.5% | 0.67 | 14.8% |
| Bitcoin (BTCUSD) | -17.1% | 42.2% | -0.33 | 14.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AVAH | |
|---|---|---|---|---|
| AVAH | -9.9% | 77.9% | 0.19 | - |
| Sector ETF (XLV) | 5.0% | 14.6% | 0.17 | 21.6% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 27.4% |
| Gold (GLD) | 20.5% | 17.9% | 0.94 | 7.8% |
| Commodities (DBC) | 14.3% | 19.1% | 0.61 | 4.2% |
| Real Estate (VNQ) | 3.5% | 18.8% | 0.09 | 25.6% |
| Bitcoin (BTCUSD) | 7.7% | 56.2% | 0.35 | 19.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AVAH | |
|---|---|---|---|---|
| AVAH | -5.1% | 77.9% | 0.19 | - |
| Sector ETF (XLV) | 9.1% | 16.5% | 0.45 | 21.6% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 27.4% |
| Gold (GLD) | 13.6% | 15.9% | 0.71 | 7.8% |
| Commodities (DBC) | 9.7% | 17.7% | 0.46 | 4.2% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.24 | 25.6% |
| Bitcoin (BTCUSD) | 67.7% | 66.9% | 1.07 | 19.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 1/14/2026 | 10.0% | 5.9% | -7.8% |
| 10/21/2025 | -7.4% | -4.1% | -17.4% |
| 8/7/2025 | 49.4% | 83.8% | 111.3% |
| 3/13/2025 | 37.4% | 47.3% | 28.3% |
| 11/7/2024 | 16.2% | 19.3% | 11.4% |
| 8/8/2024 | 32.2% | 33.5% | 58.0% |
| 3/14/2024 | -3.0% | -2.4% | -6.4% |
| 11/9/2023 | 2.0% | 27.9% | 75.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 7 | 6 |
| # Negative | 7 | 8 | 9 |
| Median Positive | 13.1% | 27.9% | 43.2% |
| Median Negative | -7.6% | -17.8% | -17.4% |
| Max Positive | 49.4% | 83.8% | 111.3% |
| Max Negative | -26.7% | -38.0% | -44.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/19/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/14/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/15/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/19/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 2.54 Bil | 2.55 Bil | 2.56 Bil | 0 | Affirmed | Guidance: 2.55 Bil for 2026 | |
| 2026 Adjusted EBITDA | 318.00 Mil | 320.00 Mil | 322.00 Mil | 0 | Affirmed | Guidance: 320.00 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 1/14/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | 2.42 Bil | 2.44 Bil | 2.44 Bil | 2.5% | Raised | Guidance: 2.38 Bil for 2025 | |
| 2025 Adjusted EBITDA | 318.00 Mil | 320.00 Mil | 322.00 Mil | 6.7% | Raised | Guidance: 300.00 Mil for 2025 | |
| 2025 Net Income | 181.00 Mil | 200.50 Mil | 220.00 Mil | ||||
| 2025 Normalized Adjusted EBITDA | 298.00 Mil | 300.00 Mil | 302.00 Mil | ||||
| 2026 Revenue | 2.54 Bil | 2.55 Bil | 2.56 Bil | ||||
| 2026 Adjusted EBITDA | 318.00 Mil | 320.00 Mil | 322.00 Mil | ||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Shaner, Jeff | Chief Executive Officer | Direct | Sell | 2192026 | 7.21 | 173,225 | 1,248,640 | 19,108,160 | Form |
| 2 | Cunningham, Patrick A | Chief Compliance Officer | Direct | Sell | 2192026 | 7.21 | 18,436 | 132,890 | 2,434,606 | Form |
| 3 | Buckhalter, Matthew | Chief Financial Officer | Direct | Sell | 2192026 | 7.21 | 13,512 | 97,397 | 3,814,889 | Form |
| 4 | Stewart, Deborah | SVP, Chief Accounting Officer | Direct | Sell | 2192026 | 7.21 | 11,181 | 80,595 | 2,175,485 | Form |
| 5 | Reisz, Edwin C | Chief Administrative Officer | Direct | Sell | 2192026 | 7.21 | 60,769 | 438,035 | 10,430,676 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.